A1G
0.53
68.3%
HWK
0.026
-21.2%
BOC
0.84
37.7%
CAN
0.009
-18.2%
RBRDA
0.015
36.4%
CYQ
0.005
-16.7%
EDU
0.82
35.5%
IPT
0.005
-16.7%
FBR
0.004
33.3%
IBX
0.022
-15.4%
M4M
0.008
33.3%
FAL
0.535
-15.1%
AYT
0.005
25%
EE1
0.006
-14.3%
GR8
0.2
25%
G88
0.006
-14.3%
PGY
0.005
25%
OVT
0.006
-14.3%
RLG
0.005
25%
HYD
0.013
-13.3%
TMX
0.005
25%
FRX
0.014
-12.5%
WLD
0.016
23.1%
RB6
0.11
-12%
PIQ
0.485
21.3%
ORP
0.045
-11.8%
YUG
0.064
20.8%
T92
0.053
-11.7%
APC
0.012
20%
HMX
0.023
-11.5%
VRC
0.006
20%
PNR
4.785
-11.2%
RGL
0.007
16.7%
ATH
0.008
-11.1%
8CO
0.029
16%
PVW
0.016
-11.1%
TTT
0.23
15%
TNC
0.56
-11.1%
LPM
0.155
14.8%
TSL
0.008
-11.1%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BOT successful completion of human factors validation study

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) announces that the Company has successfully completed the planned human factors validation study assessing the revised Instructions for Use for Sofpironium Bromide gel https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02753854-6A1186430 #shorts